Company Filing History:
Years Active: 2007-2010
Title: Anna-Karin Olsson: Innovator in Anti-Angiogenic Research
Introduction
Anna-Karin Olsson is a prominent inventor based in Uppsala, Sweden. She has made significant contributions to the field of biotechnology, particularly in the development of anti-angiogenic polypeptides. With a total of 3 patents to her name, her work has the potential to impact medical treatments significantly.
Latest Patents
One of her latest patents is titled "Endogenous peptide and active subfragments thereof." This invention relates to a substantially pure biologically active consecutive anti-angiogenic polypeptide derived from the central region of human Histidine Rich Glycoprotein (HRGP). The polypeptide exhibits anti-angiogenic activities similar to those of the mature protein. Additionally, the invention encompasses new biologically active subfragments of human HRGP, characterized by their anti-angiogenic properties. One notable subfragment is referred to as Pep2, which includes a newly identified minimal functional entity.
Another significant patent is focused on histidine-rich glycoprotein (HRGP) polypeptides and their applications. This invention outlines methods for inhibiting angiogenesis through the administration of HRGP polypeptides. It also includes pharmaceutical compositions and articles of manufacture that incorporate HRGP polypeptides, antibodies, and receptors that bind to these polypeptides.
Career Highlights
Anna-Karin Olsson is currently associated with Innoventus Project AB, where she continues her research and development efforts. Her work is pivotal in advancing the understanding and application of anti-angiogenic therapies.
Collaborations
She collaborates with esteemed colleagues, including Helena Larsson and Lena Claesson-Welsh, who contribute to her research endeavors.
Conclusion
Anna-Karin Olsson's innovative work in the field of anti-angiogenic research showcases her dedication to advancing medical science. Her patents reflect her commitment to developing effective therapeutic solutions.